Skip to main content

Latest news

Mon, 02/18/2019 - 08:46 - Tue, 02/01/2022 - 09:00

Elsalys Biotech SAS, a 2013 spinout from Transgene SA, achieved a significant milestone with the finding that lead candidate inolimomab (Leukotac)

Thu - 09, 11/08 - 09/2018 - 08:30

Dr Thierry Menguy, PhD, Head of mAb Development and Production Unit and co-founder of ELSALYS BIOTECH, has presented "Anti-CD160 alone or in combin

Mon - 07, 11/05 - 07/2018 - 09:00

Do not hesitate to contact us if you want to meet our team during Bio-Eu

Mon, 07/02/2018 - 15:00 - Fri, 07/02/2021 - 15:30
  • Efficacy and safety are consistently demonstrated in several in vivo preclinical models
  • Anti-CD160 is a potent inhibitor of ocular v
Fri, 04/20/2018 - 08:30

Not to be distributed directly or indirectly in the United States, Canada, Australia or Japan

 

Thu, 04/05/2018 - 09:00
  • ELSALYS BIOTECH plans to submit to the European Medicines Agency before summer 2018 a Paediatric Investigation Plan (PIP) proposing to c

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.